HYBRID EVENT: You can participate in person at Boston, Massachusetts, USA or Virtually from your home or work.
Ismail Osmanov, Speaker at Covid-19 Global Conference
Ismail Osmanov
Children's city clinical hospital, Russian Federation
Title : Monoclonal antibodies efficacy in treatment of novel coronavirus infection (COVID-19) in children at risk of developing a severe course of the disease

Abstract:

Virus-neutralizing monoclonal antibodies (mAbs) are designed to create a passive or enhance the natural immune response against a foreign agent. For the first time, the introduction of monoclonal antibodies to children for the treatment of new coronavirus infection (hereinafter referred to as COVID-19) has become available in medical organizations of the Moscow state healthcare system since November 2021.

The study presents the treatment results of 98 patients at risk for developing a severe course of COVID-19 with a first positive result of polymerase chain reaction (SARS-CoV-2) on the basis of a short-stay hospital of a multidisciplinary children's city clinical hospital named after Z.A. Bashlyaeva of Moscow Healthcare Department. In order to prevent the clinical manifestation of COVID-19 and the progression of the underlying disease, all of these children were treated with virus-neutralizing monoclonal antibodies.

Patients underwent a comprehensive clinical, laboratory and instrumental examination both at baseline and in dynamics on days 3-7-11 after mAbs therapy according to the developed clinical algorithm. Evaluation of the effectiveness of biological therapy was carried out according to the dynamics of the clinical symptoms of the disease, the results of the chest CT scan, as well as laboratory markers during treatment. In addition, the timing of the virus elimination the body was estimated.

The effectiveness of ongoing biological therapy in children at risk for severe course of COVID-19 was noted in 100% of cases. None of the observed patients had either a clinical manifestation of COVID-19 or a relapse of the underlying chronic disease.

Audience Take Away:

  • Identify children at risk for developing a severe course of COVID-19
  • Develop a plan for examining patients of this category
  • Formulate indications for the early appointment of virus-neutralizing monoclonal antibodies, based on the examination results
  • Evaluate the effectiveness of ongoing therapy in children at risk for developing a severe course of COVID-19

Biography:

Ismail Osmanov graduated from the Dagestan State Medical Institute in 1983. In 1996 he received his doctorate in pediatrics. From 1991 to 1993 he trained in the USA at the University of Buffalo (New York State). He is the chief pediatrician, nephrologist of the Moscow Department of Health, honorary professor at the University of Buffalo (New York, USA), director of the University Clinic of the Russian National Research Medical University named after N.I. Pirogov, editor-in-chief of the Pediatric Practice journal, member of the editorial board of a number of medical journals. He has more than 350 published scientific papers.

Watsapp